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Abstract
Neurodegenerative disorders, such as Alzheimer’s Disease, effect over 50 million Americans
a year, and despite the high prevalence, the pathogenesis of these diseases remains unclear. How-
ever, researchers have noticed a dramatic up-regulation of a protein called translocator protein
(TSPO) under neurodegenerative and neuro-inflammatory conditions. While TSPO expression is
prevalent in the brain, it is still unclear as to what exact types of cells TSPO is expressed in, and
what mechanisms result in increased expression. Regulating the expression or function of TSPO
is believed to have an impact on neurodegenerative processes, but definitive evidence of this is
also limited. To advance our understanding we will examine what cells TSPO is expressed in,
and reveal what effects TSPO agonists and antagonists will have on brain activity patterns us-
ing electroencephalography. Some research has found that certain TSPO ligands have potential
to be therapeutic agents for neurodegeneration, neuro-inflammation and neurotrauma. Therefore,
localization of TSPO in brain tissue and investigation of the mechanism by which it becomes ac-
tivated, may allow for the development of novel treatments for neurodegenerative issues such as
Alzheimer’s.
KEYWORDS: Translocator protein; neurodegeneration; neuro-inflammation; neurotrauma; Alzheimer’s
Disease
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ABSTRACT   
Neurodegenerative disorders, such as Alzheimer's Disease, effect over 50 million 
Americans a year, and despite the high prevalence, the pathogenesis of these diseases remains 
unclear. However, researchers have noticed a dramatic up-regulation of a protein called 
translocator protein (TSPO) under neurodegenerative and neuro-inflammatory conditions. While 
TSPO expression is prevalent in the brain, it is still unclear as to what exact types of cells TSPO 
is expressed in, and what mechanisms result in increased expression. Regulating the expression or 
function of TSPO is believed to have an impact on neurodegenerative processes, but definitive 
evidence of this is also limited. To advance our understanding we will examine what cells TSPO 
is expressed in, and reveal what effects TSPO agonists and antagonists will have on brain activity 
patterns using electroencephalography. Some research has found that certain TSPO ligands have 
potential to be therapeutic agents for neurodegeneration, neuro-inflammation and neurotrauma. 
Therefore, localization of TSPO in brain tissue and investigation of the mechanism by which it 
becomes activated, may allow for the development of novel treatments for neurodegenerative 
issues such as Alzheimer's. 
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